Nurix Therapeutics (NRIX) Stock Forecast & Price Target

Compare

548 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NRIX Analyst Ratings

Strong Buy

13 Buy

0 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Nurix

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NRIX Stock 12 Month Forecast

Average Price Target

$31.08

▲(99.21% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Nurix Therapeutics in the last 3 months. The average price target is $31.08 with a high forecast of $41.00 and a low forecast of $22.00. The average price target represents a 99.21% change from the last price of $15.60.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","25":"$25","42":"$42","16.5":"$16.5","33.5":"$33.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$41.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.076923076923077,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$31.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$22.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,16.5,25,33.5,42],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.09,18.92923076923077,20.768461538461537,22.607692307692307,24.446923076923078,26.286153846153844,28.125384615384615,29.964615384615385,31.803846153846152,33.64307692307692,35.48230769230769,37.321538461538466,39.16076923076923,{"y":41,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.09,18.165917159763314,19.241834319526628,20.317751479289942,21.393668639053253,22.469585798816567,23.54550295857988,24.621420118343195,25.69733727810651,26.773254437869824,27.849171597633138,28.925088757396452,30.001005917159766,{"y":31.076923076923077,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.09,17.467692307692307,17.845384615384614,18.223076923076924,18.60076923076923,18.978461538461538,19.356153846153845,19.733846153846155,20.111538461538462,20.48923076923077,20.866923076923076,21.244615384615386,21.622307692307693,{"y":22,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.71,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.47,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.04,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.11,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.94,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.91,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.97,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.09,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$41.00

Average Price Target$31.08

Lowest Price Target$22.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Terence Flynn

Morgan Stanley

$36

Buy

130.77%

Upside

Reiterated

01/30/26

Analysts Are Bullish on Top Healthcare Stocks: Olema Pharmaceuticals (OLMA), Nurix Therapeutics (NRIX)

Derek Archila

Wells Fargo

$30→$29

Buy

85.90%

Upside

Reiterated

01/29/26

Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (NASDAQ: ARQT), Nurix Therapeutics (NASDAQ: NRIX) and Madrigal Pharmaceuticals (NASDAQ: MDGL)

Gregory Renza

Truist Financial

$30

Buy

92.31%

Upside

Reiterated

01/29/26

Truist Financial Sticks to Its Buy Rating for Nurix Therapeutics (NRIX)

Jeet Mukherjee

BTIG

$30

Buy

92.31%

Upside

Reiterated

01/29/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Robert Burns

H.C. Wainwright

$31→$32

Buy

105.13%

Upside

Reiterated

01/29/26

Nurix Therapeutics price target raised to $32 from $31 at H.C. WainwrightNurix Therapeutics price target raised to $32 from $31 at H.C. Wainwright

Joseph Catanzaro

Mizuho Securities

$30

Buy

92.31%

Upside

Reiterated

01/29/26

Nurix Therapeutics (NRIX) Receives a Buy from Mizuho Securities

Matthew Biegler

Oppenheimer

$28

Buy

79.49%

Upside

Reiterated

01/29/26

Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (NYSE: HNGE), Nurix Therapeutics (NASDAQ: NRIX) and Thermo Fisher (NYSE: TMO)

Stephen Willey

Stifel Nicolaus

$33→$35

Buy

124.36%

Upside

Reiterated

01/29/26

Analysts Are Bullish on These Healthcare Stocks: Danaher (DHR), Nurix Therapeutics (NRIX)

Gil Blum

Needham

$26

Buy

66.67%

Upside

Reiterated

01/29/26

Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NASDAQ: NRIX), Sanofi (Other OTC: SNYNF) and Conmed (NYSE: CNMD)

Biren Amin

Piper Sandler

$32→$35

Buy

124.36%

Upside

Reiterated

01/29/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Brian Abrahams

RBC Capital

$28→$30

Buy

92.31%

Upside

Reiterated

01/28/26

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (NASDAQ: PVLA), Nurix Therapeutics (NASDAQ: NRIX) and Jazz Pharmaceuticals (NASDAQ: JAZZ)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$41

Buy

162.82%

Upside

Reiterated

12/04/25

Nurix Therapeutics (NRIX) Gets a Buy from Jefferies

Tessa Romero

J.P. Morgan

$30→$22

Buy

41.03%

Upside

Reiterated

11/18/25

Nurix Therapeutics price target lowered to $22 from $30 at JPMorganNurix Therapeutics price target lowered to $22 from $30 at JPMorgan

David Dai

UBS

$26→$23

Buy

47.44%

Upside

Reiterated

11/10/25

Analysts Offer Insights on Healthcare Companies: Catalyst Pharma (NASDAQ: CPRX), Rapid Micro Biosystems (NASDAQ: RPID) and Nurix Therapeutics (NASDAQ: NRIX)

Faisal Khurshid

Leerink Partners

$12

Hold

-23.08%

Downside

Reiterated

10/23/25

Leerink Partners Sticks to Their Hold Rating for Nurix Therapeutics (NRIX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Terence Flynn

Morgan Stanley

$36

Buy

130.77%

Upside

Reiterated

01/30/26

Analysts Are Bullish on Top Healthcare Stocks: Olema Pharmaceuticals (OLMA), Nurix Therapeutics (NRIX)

Derek Archila

Wells Fargo

$30→$29

Buy

85.90%

Upside

Reiterated

01/29/26

Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (NASDAQ: ARQT), Nurix Therapeutics (NASDAQ: NRIX) and Madrigal Pharmaceuticals (NASDAQ: MDGL)

Gregory Renza

Truist Financial

$30

Buy

92.31%

Upside

Reiterated

01/29/26

Truist Financial Sticks to Its Buy Rating for Nurix Therapeutics (NRIX)

Jeet Mukherjee

BTIG

$30

Buy

92.31%

Upside

Reiterated

01/29/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Robert Burns

H.C. Wainwright

$31→$32

Buy

105.13%

Upside

Reiterated

01/29/26

Nurix Therapeutics price target raised to $32 from $31 at H.C. WainwrightNurix Therapeutics price target raised to $32 from $31 at H.C. Wainwright

Joseph Catanzaro

Mizuho Securities

$30

Buy

92.31%

Upside

Reiterated

01/29/26

Nurix Therapeutics (NRIX) Receives a Buy from Mizuho Securities

Matthew Biegler

Oppenheimer

$28

Buy

79.49%

Upside

Reiterated

01/29/26

Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (NYSE: HNGE), Nurix Therapeutics (NASDAQ: NRIX) and Thermo Fisher (NYSE: TMO)

Stephen Willey

Stifel Nicolaus

$33→$35

Buy

124.36%

Upside

Reiterated

01/29/26

Analysts Are Bullish on These Healthcare Stocks: Danaher (DHR), Nurix Therapeutics (NRIX)

Gil Blum

Needham

$26

Buy

66.67%

Upside

Reiterated

01/29/26

Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NASDAQ: NRIX), Sanofi (Other OTC: SNYNF) and Conmed (NYSE: CNMD)

Biren Amin

Piper Sandler

$32→$35

Buy

124.36%

Upside

Reiterated

01/29/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Brian Abrahams

RBC Capital

$28→$30

Buy

92.31%

Upside

Reiterated

01/28/26

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (NASDAQ: PVLA), Nurix Therapeutics (NASDAQ: NRIX) and Jazz Pharmaceuticals (NASDAQ: JAZZ)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$41

Buy

162.82%

Upside

Reiterated

12/04/25

Nurix Therapeutics (NRIX) Gets a Buy from Jefferies

Tessa Romero

J.P. Morgan

$30→$22

Buy

41.03%

Upside

Reiterated

11/18/25

Nurix Therapeutics price target lowered to $22 from $30 at JPMorganNurix Therapeutics price target lowered to $22 from $30 at JPMorgan

David Dai

UBS

$26→$23

Buy

47.44%

Upside

Reiterated

11/10/25

Analysts Offer Insights on Healthcare Companies: Catalyst Pharma (NASDAQ: CPRX), Rapid Micro Biosystems (NASDAQ: RPID) and Nurix Therapeutics (NASDAQ: NRIX)

Faisal Khurshid

Leerink Partners

$12

Hold

-23.08%

Downside

Reiterated

10/23/25

Leerink Partners Sticks to Their Hold Rating for Nurix Therapeutics (NRIX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Nurix Therapeutics

3 Months

xxx

Success Rate

9/15 ratings generated profit

Average Return

+23.91%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +23.91% per trade.

1 Year

Peter LawsonBarclays

Success Rate

10/16 ratings generated profit

Average Return

+30.93%

a rating ―

Copying Peter Lawson's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +30.93% per trade.

2 Years

xxx

Success Rate

15/19 ratings generated profit

Average Return

+46.38%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 78.95% of your transactions generating a profit, with an average return of +46.38% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NRIX Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NRIX has received 25 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. NRIX average Analyst price target in the past 3 months is 31.08.

Each month's total comprises the sum of three months' worth of ratings.

NRIX Financial Forecast

NRIX Earnings Forecast

Next quarter’s earnings estimate for NRIX is -$0.77 with a range of -$0.89 to -$0.65. The previous quarter’s EPS was -$0.82. NRIX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year NRIX has Performed in-line its overall industry.

NRIX Sales Forecast

Next quarter’s sales forecast for NRIX is $14.25M with a range of $2.75M to $22.50M. The previous quarter’s sales results were $13.58M. NRIX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year NRIX has Performed in-line its overall industry.

NRIX Stock Forecast FAQ

What is NRIX’s average 12-month price target, according to analysts?

Based on analyst ratings, Nurix Therapeutics, Inc.’s 12-month average price target is 31.08.

What is NRIX’s upside potential, based on the analysts’ average price target?

Nurix Therapeutics, Inc. has 99.21% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NRIX a Buy, Sell or Hold?

Nurix Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.

What is Nurix Therapeutics, Inc.’s price target?

The average price target for Nurix Therapeutics, Inc. is 31.08. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $41.00 ,the lowest forecast is $22.00. The average price target represents 99.21% Increase from the current price of $15.6.

What do analysts say about Nurix Therapeutics, Inc.?

Nurix Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of NRIX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Nurix Therapeutics (NRIX) Stock Forecast & Price Target

NRIX Analyst Ratings

NRIX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Nurix Therapeutics

NRIX Analyst Recommendation Trends

NRIX Financial Forecast

NRIX Earnings Forecast

NRIX Sales Forecast

NRIX Stock Forecast FAQ

Detailed List of Analyst Forecasts